查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1706760

激酶抑制剂市场－全球产业分析、规模、份额、成长、趋势及预测（2024-2034）

Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 219 Pages | 商品交期: 2-10个工作天内

价格

激酶抑制剂市场 - 报告范围

TMR 关于全球激酶抑制剂市场的报告研究了过去和当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。该报告提供了 2018 年至 2034 年期间全球激酶抑制剂市场的收入，以 2024 年为基准年，2034 年为预测年。该报告也提供了 2024 年至 2034 年全球激酶抑制剂市场的年复合成长率(CAGR%)。

该报告是经过广泛研究后编写的。初步研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了访谈。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解激酶抑制剂市场。

市场概况
2023年市场价值 580.901亿美元
2034年的市场价值 899.298亿美元
复合年增长率 3.9%

该报告深入探讨了全球激酶抑制剂市场的竞争格局。我们已经确定了在全球激酶抑製剂市场中运营的关键参与者，并根据各种属性对每个参与者进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球激酶抑制剂市场参与者的属性。

目录

第一章：前言

第二章：假设与研究方法

第三章：执行摘要：全球市场

第四章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年全球市场分析与预测

第五章：关键见解

  • 重要行业活动
  • PESTEL分析
  • 主要国家/地区监管情况
  • 波特五力分析
  • 产品/品牌分析
  • 供应链分析
  • 管道分析

第六章：全球市场分析与预测：依类型

  • 介绍与定义
  • 主要发现/进展
  • 2020-2034年各类型市场价值预测
    • 非受体酪胺酸
      • 布鲁顿酪胺酸激酶（BTK）抑制剂
      • BCR-ABL
      • Janus激酶（JAK）抑制剂
      • 间质上皮转化生长因子（c-MET）
      • 脾臟酪胺酸激酶（SYK）抑制剂
      • 其他的
    • 酪胺酸受体
      • 血管内皮生长因子受体
      • 血小板衍生生长因子受体
      • 表皮生长因子受体
      • ALK
      • 其他的
    • 多
    • 丝胺酸/苏胺酸
    • 蛋白激酶C抑制剂
    • RHO
    • 其他的
  • 不同类型的市场吸引力

第七章：全球市场分析与预测：依管理途径

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2034 年按给药途径分類的市场价值预测
    • 口服
    • 肠外及其他
  • 按给药途径分類的市场吸引力

第八章：全球市场分析与预测：按应用

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2034 年各应用市场价值预测
    • 肿瘤学
      • 乳癌
      • 白血病
      • 肾癌
      • 肺癌
      • 黑色素瘤
      • 大肠直肠癌
      • 其他的
    • 发炎性疾病
    • 其他的
  • 按应用分類的市场吸引力

第九章：全球市场分析与预测：按最终用户

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2034 年终端用户市值预测
    • 医院药房
    • 独立药局
    • 网路药局
  • 最终用户的市场吸引力

第十章：全球市场分析与预测：按地区

  • 主要发现
  • 各地区市场价值预测
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 各地区市场吸引力

第 11 章：北美市场分析与预测

  • 我们
  • 加拿大

第十二章：欧洲市场分析与预测

  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区

第十三章：亚太市场分析与预测

  • 中国
  • 印度
  • 日本
  • 澳洲和纽西兰
  • 亚太其他地区

第十四章：拉丁美洲市场分析与预测

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区

第十五章：中东与非洲市场分析与预测

  • 海湾合作委员会国家
  • 南非
  • 中东和非洲其他地区

第 16 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 各公司市占率分析（2023 年）
  • 公司简介
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • AstraZeneca plc
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Johnson & Johnson Service, Inc.
    • Merck & Co., Inc.
    • Takeda Pharmaceuticals
    • Eisai Co., Ltd.
    • GSK Plc.
    • Eli Lilly
    • Alcon
Product Code: TMRGL818

Kinase Inhibitors Market - Scope of Report

TMR's report on the global kinase inhibitors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kinase inhibitors market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kinase inhibitors market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kinase inhibitors market.

Market Snapshot
Market Value in 2023US$ 58090.1 Mn
Market Value in 2034US$ 89929.8 Mn
CAGR3.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kinase inhibitors market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kinase inhibitors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kinase inhibitors market.

The report delves into the competitive landscape of the global kinase inhibitors market. Key players operating in the global kinase inhibitors market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kinase inhibitors market profiled in this report.

Key Questions Answered in Global kinase inhibitors Market Report:

  • What is the sales/revenue generated by kinase inhibitors across all regions during the forecast period?
  • What are the opportunities in the global kinase inhibitors market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Kinase Inhibitors Market - Research Objectives and Research Approach

The comprehensive report on the global kinase inhibitors market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kinase inhibitors market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kinase inhibitors market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Kinase Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Kinase Inhibitors Market Analysis and Forecasts, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. PESTEL Analysis
  • 5.3. Regulatory Scenario by Key Countries/Regions
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. Product/Brand Analysis
  • 5.6. Supply Chain Analysis
  • 5.7. Pipeline Analysis

6. Global Kinase Inhibitors Market Analysis and Forecasts, By Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2020-2034
    • 6.3.1. Non-receptor Tyrosine Kinase Inhibitors
      • 6.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 6.3.1.2. BCR-ABL
      • 6.3.1.3. Janus Kinase (JAK) Inhibitor
      • 6.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 6.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 6.3.1.6. Others
    • 6.3.2. Receptor Tyrosine Kinase Inhibitors
      • 6.3.2.1. VEGFR
      • 6.3.2.2. PDGFR
      • 6.3.2.3. EGFR
      • 6.3.2.4. ALK
      • 6.3.2.5. Others
    • 6.3.3. Multikinase Inhibitors
    • 6.3.4. Serine/Threonine Kinase Inhibitors
    • 6.3.5. Protein Kinase C Inhibitors
    • 6.3.6. RHO Kinase Inhibitors
    • 6.3.7. Others
  • 6.4. Market Attractiveness By Type

7. Global Kinase Inhibitors Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020-2034
    • 7.3.1. Oral
    • 7.3.2. Parenteral & Others
  • 7.4. Market Attractiveness By Route of Administration

8. Global Kinase Inhibitors Market Analysis and Forecasts, By Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Application, 2020-2034
    • 8.3.1. Oncology
      • 8.3.1.1. Breast Cancer
      • 8.3.1.2. Leukemia
      • 8.3.1.3. Renal Cancers
      • 8.3.1.4. Lung Cancer
      • 8.3.1.5. Melanoma
      • 8.3.1.6. Colorectal Cancer
      • 8.3.1.7. Others
    • 8.3.2. Inflammatory Disorders
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Application

9. Global Kinase Inhibitors Market Analysis and Forecasts, By End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By End-user, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Independent Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness By End-user

10. Global Kinase Inhibitors Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Kinase Inhibitors Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Type, 2020-2034
    • 11.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 11.2.1.2. BCR-ABL
      • 11.2.1.3. Janus Kinase (JAK) Inhibitor
      • 11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 11.2.1.6. Others
    • 11.2.2. Receptor Tyrosine Kinase Inhibitors
      • 11.2.2.1. VEGFR
      • 11.2.2.2. PDGFR
      • 11.2.2.3. EGFR
      • 11.2.2.4. ALK
      • 11.2.2.5. Others
    • 11.2.3. Multikinase Inhibitors
    • 11.2.4. Serine/Threonine Kinase Inhibitors
    • 11.2.5. Protein Kinase C Inhibitors
    • 11.2.6. RHO Kinase Inhibitors
    • 11.2.7. Others
  • 11.3. Market Value Forecast By Route of Administration, 2020-2034
    • 11.3.1. Oral
    • 11.3.2. Parenteral & Others
  • 11.4. Market Value Forecast By Application, 2020-2034
    • 11.4.1. Oncology
      • 11.4.1.1. Breast Cancer
      • 11.4.1.2. Leukemia
      • 11.4.1.3. Renal Cancers
      • 11.4.1.4. Lung Cancer
      • 11.4.1.5. Melanoma
      • 11.4.1.6. Colorectal Cancer
      • 11.4.1.7. Others
    • 11.4.2. Inflammatory Disorders
    • 11.4.3. Others
  • 11.5. Market Value Forecast By End-user, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Independent Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast By Country, 2020-2034
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Kinase Inhibitors Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Type, 2020-2034
    • 12.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 12.2.1.2. BCR-ABL
      • 12.2.1.3. Janus Kinase (JAK) Inhibitor
      • 12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 12.2.1.6. Others
    • 12.2.2. Receptor Tyrosine Kinase Inhibitors
      • 12.2.2.1. VEGFR
      • 12.2.2.2. PDGFR
      • 12.2.2.3. EGFR
      • 12.2.2.4. ALK
      • 12.2.2.5. Others
    • 12.2.3. Multikinase Inhibitors
    • 12.2.4. Serine/Threonine Kinase Inhibitors
    • 12.2.5. Protein Kinase C Inhibitors
    • 12.2.6. RHO Kinase Inhibitors
    • 12.2.7. Others
  • 12.3. Market Value Forecast By Route of Administration, 2020-2034
    • 12.3.1. Oral
    • 12.3.2. Parenteral & Others
  • 12.4. Market Value Forecast By Application, 2020-2034
    • 12.4.1. Oncology
      • 12.4.1.1. Breast Cancer
      • 12.4.1.2. Leukemia
      • 12.4.1.3. Renal Cancers
      • 12.4.1.4. Lung Cancer
      • 12.4.1.5. Melanoma
      • 12.4.1.6. Colorectal Cancer
      • 12.4.1.7. Others
    • 12.4.2. Inflammatory Disorders
    • 12.4.3. Others
  • 12.5. Market Value Forecast By End-user, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Independent Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Kinase Inhibitors Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Type, 2020-2034
    • 13.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 13.2.1.2. BCR-ABL
      • 13.2.1.3. Janus Kinase (JAK) Inhibitor
      • 13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 13.2.1.6. Others
    • 13.2.2. Receptor Tyrosine Kinase Inhibitors
      • 13.2.2.1. VEGFR
      • 13.2.2.2. PDGFR
      • 13.2.2.3. EGFR
      • 13.2.2.4. ALK
      • 13.2.2.5. Others
    • 13.2.3. Multikinase Inhibitors
    • 13.2.4. Serine/Threonine Kinase Inhibitors
    • 13.2.5. Protein Kinase C Inhibitors
    • 13.2.6. RHO Kinase Inhibitors
    • 13.2.7. Others
  • 13.3. Market Value Forecast By Route of Administration, 2020-2034
    • 13.3.1. Oral
    • 13.3.2. Parenteral & Others
  • 13.4. Market Value Forecast By Application, 2020-2034
    • 13.4.1. Oncology
      • 13.4.1.1. Breast Cancer
      • 13.4.1.2. Leukemia
      • 13.4.1.3. Renal Cancers
      • 13.4.1.4. Lung Cancer
      • 13.4.1.5. Melanoma
      • 13.4.1.6. Colorectal Cancer
      • 13.4.1.7. Others
    • 13.4.2. Inflammatory Disorders
    • 13.4.3. Others
  • 13.5. Market Value Forecast By End-user, 2020-2034
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Independent Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Kinase Inhibitors Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Type, 2020-2034
    • 14.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 14.2.1.2. BCR-ABL
      • 14.2.1.3. Janus Kinase (JAK) Inhibitor
      • 14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 14.2.1.6. Others
    • 14.2.2. Receptor Tyrosine Kinase Inhibitors
      • 14.2.2.1. VEGFR
      • 14.2.2.2. PDGFR
      • 14.2.2.3. EGFR
      • 14.2.2.4. ALK
      • 14.2.2.5. Others
    • 14.2.3. Multikinase Inhibitors
    • 14.2.4. Serine/Threonine Kinase Inhibitors
    • 14.2.5. Protein Kinase C Inhibitors
    • 14.2.6. RHO Kinase Inhibitors
    • 14.2.7. Others
  • 14.3. Market Value Forecast By Route of Administration, 2020-2034
    • 14.3.1. Oral
    • 14.3.2. Parenteral & Others
  • 14.4. Market Value Forecast By Application, 2020-2034
    • 14.4.1. Oncology
      • 14.4.1.1. Breast Cancer
      • 14.4.1.2. Leukemia
      • 14.4.1.3. Renal Cancers
      • 14.4.1.4. Lung Cancer
      • 14.4.1.5. Melanoma
      • 14.4.1.6. Colorectal Cancer
      • 14.4.1.7. Others
    • 14.4.2. Inflammatory Disorders
    • 14.4.3. Others
  • 14.5. Market Value Forecast By End-user, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Independent Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Type, 2020-2034
    • 15.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 15.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 15.2.1.2. BCR-ABL
      • 15.2.1.3. Janus Kinase (JAK) Inhibitor
      • 15.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 15.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 15.2.1.6. Others
    • 15.2.2. Receptor Tyrosine Kinase Inhibitors
      • 15.2.2.1. VEGFR
      • 15.2.2.2. PDGFR
      • 15.2.2.3. EGFR
      • 15.2.2.4. ALK
      • 15.2.2.5. Others
    • 15.2.3. Multikinase Inhibitors
    • 15.2.4. Serine/Threonine Kinase Inhibitors
    • 15.2.5. Protein Kinase C Inhibitors
    • 15.2.6. RHO Kinase Inhibitors
    • 15.2.7. Others
  • 15.3. Market Value Forecast By Route of Administration, 2020-2034
    • 15.3.1. Oral
    • 15.3.2. Parenteral & Others
  • 15.4. Market Value Forecast By Application, 2020-2034
    • 15.4.1. Oncology
      • 15.4.1.1. Breast Cancer
      • 15.4.1.2. Leukemia
      • 15.4.1.3. Renal Cancers
      • 15.4.1.4. Lung Cancer
      • 15.4.1.5. Melanoma
      • 15.4.1.6. Colorectal Cancer
      • 15.4.1.7. Others
    • 15.4.2. Inflammatory Disorders
    • 15.4.3. Others
  • 15.5. Market Value Forecast By End-user, 2020-2034
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Independent Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Type
    • 15.7.2. By Route of Administration
    • 15.7.3. By Application
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Boehringer Ingelheim International GmbH
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. AstraZeneca plc
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Pfizer, Inc.
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. F. Hoffmann-La Roche Ltd
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Bristol-Myers Squibb Company
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Bayer AG
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Johnson & Johnson Service, Inc.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Merck & Co., Inc.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Takeda Pharmaceuticals
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. Eisai Co., Ltd.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments
    • 16.3.12. GSK Plc.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Financial Overview
      • 16.3.12.3. Product Portfolio
      • 16.3.12.4. Business Strategies
      • 16.3.12.5. Recent Developments
    • 16.3.13. Eli Lilly
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Financial Overview
      • 16.3.13.3. Product Portfolio
      • 16.3.13.4. Business Strategies
      • 16.3.13.5. Recent Developments
    • 16.3.14. Alcon
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Financial Overview
      • 16.3.14.3. Product Portfolio
      • 16.3.14.4. Business Strategies
      • 16.3.14.5. Recent Developments

List of Tables

  • Table 01: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 02: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 03: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 04: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 05: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 06: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 07: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 08: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Region, 2020-2034
  • Table 09: North America - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 10: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 11: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 12: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 13: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 14: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 15: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 17: Europe - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 18: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 19: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 20: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 21: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 22: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 25: Asia Pacific - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 26: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 27: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 28: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 29: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 33: Latin America - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 34: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 35: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 36: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 41: Middle East & Africa - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 42: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 43: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034

List of Figures

  • Figure 01: Global Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 02: Global Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 03: Global Kinase Inhibitors Market Revenue (US$ Mn), by Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Figure 04: Global Kinase Inhibitors Market Revenue (US$ Mn), by Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Figure 05: Global Kinase Inhibitors Market Revenue (US$ Mn), by Multikinase Inhibitors, 2020-2034
  • Figure 06: Global Kinase Inhibitors Market Revenue (US$ Mn), by Serine/Threonine Kinase Inhibitors, 2020-2034
  • Figure 07: Global Kinase Inhibitors Market Revenue (US$ Mn), by Protein Kinase C Inhibitors, 2020-2034
  • Figure 08: Global Kinase Inhibitors Market Revenue (US$ Mn), by RHO Kinase Inhibitors, 2020-2034
  • Figure 09: Global Kinase Inhibitors Market Revenue (US$ Mn), by Others, 2020-2034
  • Figure 10: Global Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 11: Global Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 12: Global Kinase Inhibitors Market Revenue (US$ Mn), by Oral, 2020-2034
  • Figure 13: Global Kinase Inhibitors Market Revenue (US$ Mn), by Parenteral, 2020-2034
  • Figure 14: Global Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 15: Global Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 16: Global Kinase Inhibitors Market Revenue (US$ Mn), by Breast Cancer, 2020-2034
  • Figure 17: Global Kinase Inhibitors Market Revenue (US$ Mn), by Chronic myeloid leukemia (CML), 2020-2034
  • Figure 18: Global Kinase Inhibitors Market Revenue (US$ Mn), by Renal Cancers, 2020-2034
  • Figure 19: Global Kinase Inhibitors Market Revenue (US$ Mn), by Lung Cancer, 2020-2034
  • Figure 20: Global Kinase Inhibitors Market Revenue (US$ Mn), by Metastatic melanoma, 2020-2034
  • Figure 21: Global Kinase Inhibitors Market Revenue (US$ Mn), by Soft tissue sarcoma, 2020-2034
  • Figure 22: Global Kinase Inhibitors Market Revenue (US$ Mn), by Others, 2020-2034
  • Figure 23: Global Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 24: Global Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 25: Global Kinase Inhibitors Market Revenue (US$ Mn), by Hospital Pharmacies, 2020-2034
  • Figure 26: Global Kinase Inhibitors Market Revenue (US$ Mn), by Independent Pharmacies, 2020-2034
  • Figure 27: Global Kinase Inhibitors Market Revenue (US$ Mn), by Online Pharmacies, 2020-2034
  • Figure 28: Global Kinase Inhibitors Market Value Share Analysis, By Region, 2023 and 2034
  • Figure 29: Global Kinase Inhibitors Market Attractiveness Analysis, By Region, 2024-2034
  • Figure 30: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 31: North America Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 32: North America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 33: North America Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 34: North America Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 35: North America Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 36: North America Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 37: North America Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 38: North America Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 39: North America Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 40: North America Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 41: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 42: Europe Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 43: Europe Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 44: Europe Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 45: Europe Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 46: Europe Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 47: Europe Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 48: Europe Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 49: Europe Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 50: Europe Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 51: Europe Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 52: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 53: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 54: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 55: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 56: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 57: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 58: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 59: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 60: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 61: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 62: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 63: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 64: Latin America Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 65: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 66: Latin America Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 67: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 68: Latin America Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 69: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 70: Latin America Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 71: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 72: Latin America Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 73: Latin America Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 74: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 75: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 76: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 77: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 78: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 79: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 80: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 81: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 82: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 83: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 84: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034